Processa Pharmaceuticals Inc
$ 2.77
-6.73%
10 Apr - close price
- Market Cap 7,368,300 USD
- Current Price $ 2.77
- High / Low $ 2.98 / 2.74
- Stock P/E N/A
- Book Value 2.17
- EPS -10.36
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.58 %
- ROE -3.73 %
- 52 Week High 19.62
- 52 Week Low 1.76
About
Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients with unmet medical needs in the United States. The company is headquartered in Hanover, Maryland.
Analyst Target Price
$25.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-11 | 2025-05-08 | 2025-03-27 | 2024-10-30 | 2024-08-13 | 2024-05-10 | 2024-03-29 | 2023-11-13 | 2023-08-10 | 2023-05-15 | 2023-03-30 |
| Reported EPS | -0.07 | -0.25 | -0.3 | -0.74 | -1.03 | -1.01 | -1.11 | -1.7 | -0.08 | -0.097 | -0.18 | -0.36 |
| Estimated EPS | -0.45 | -0.23 | -1.18 | -0.92 | -1 | -0.98 | -1.18 | -1.6 | -0.1 | -0.23 | -0.28 | -0.32 |
| Surprise | 0.38 | -0.02 | 0.88 | 0.18 | -0.03 | -0.03 | 0.07 | -0.1 | 0.02 | 0.133 | 0.1 | -0.04 |
| Surprise Percentage | 84.4444% | -8.6957% | 74.5763% | 19.5652% | -3% | -3.0612% | 5.9322% | -6.25% | 20% | 57.8261% | 35.7143% | -12.5% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 1.0 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: PCSA
2026-04-03 15:40:18
Processa Pharmaceuticals (PCSA) insiders have significantly increased their stock holdings, with CEO Ng George K purchasing 2,136 shares and executives collectively buying 16,175 shares. This show of confidence has led to a positive market reaction, with the stock closing up 6% and surging 10% in after-hours trading. Retail sentiment on Stocktwits also shifted from 'bearish' to 'bullish' despite the stock's year-long decline.
2026-04-02 22:09:31
Processa Pharmaceuticals' Chief Business - Strategy Officer, Patrick Lin, purchased 1,603 shares of company stock for $4,063 at a price of $2.535 per share. This transaction increases Lin's direct holdings to 3,356 shares and indirect holdings to 1,740 shares through a family trust. The company also recently completed enrollment for a Phase 2 clinical study of NGC-Cap for advanced breast cancer.
2026-04-02 15:10:48
Processa Pharmaceuticals' Chief Business & Strategy Officer, Patrick Lin, purchased 1,603 shares of common stock at $2.535 per share in an open-market transaction. Following this purchase, he directly holds 3,356 shares and indirectly holds an additional 1,740 shares through the Lin Family Trust. This transaction, detailed in a Form 4 SEC filing, signals insider confidence in the company.
2026-04-02 15:10:48
Processa Pharmaceuticals' Chief Business - Strategy Officer, Patrick Lin, recently purchased 1,603 shares of PCSA common stock for $4,063, increasing his direct holdings to 3,356 shares. This transaction occurred as the stock showed a 9.8% gain over the past week, despite a 49% drop over six months. Separately, the company completed enrollment and dosing for an interim analysis in its Phase 2 clinical study for advanced breast cancer treatment.
2026-04-02 08:09:31
Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) director Geraldine Pannu recently bought 2,072 shares of common stock for $5,252. This purchase occurred as the stock shows a recent gain, despite a significant annual decline, and comes after the company completed enrollment for an interim analysis in a Phase 2 clinical study for breast cancer treatment.
2026-04-02 02:40:40
Patrick Lin, Chief Business - Strategy Officer at Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), purchased 1,603 shares for $4,063 on March 31, 2026. The company is also progressing with its Phase 2 clinical study of NGC-Cap for advanced breast cancer, having completed enrollment and dosing for an interim analysis. InvestingPro analysis indicates that Processa Pharmaceuticals holds more cash than debt and appears undervalued.
